Pharma BD Deal Intelligence
Otsuka's $886M Astex buy is a quiet win: the fragment-based discovery platform delivered two approved drugs post-close—Balversa (erdafitinib, first FGFR inhibitor approved, 2019) and Inqovi (decitabine/cedazuridine, 2020)—and in 2026 the folded-in unit signed a new $25M-upfront Genentech collaboration, proving the platform still generates deal flow 13 years later.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Sarissa Capital, holder of approximately 5% of Astex shares, said the announced merger with Otsuka significantly undervalues Astex and that it did not intend…
ASTRAL-1 missed CR and OS endpoints in treatment-naive unfit AML — a setback for Otsuka's $866M Astex deal, though Astex's Mohammad Azab pointed to 'very…
Guadecitabine has now failed three late-phase trials, leaving Otsuka 'facing the prospect of being unable to generate a return on the lead clinical program…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Otsuka to acquire Astex at $8.50/share cash (~$886M); brings SGI-110 hypomethylating agent and Pyramid fragment-based platform plus oncology/CNS pipeline.
Assessment window: 5yr post-close.
22K US cases/yr
Acute myeloid leukemia is an aggressive cancer of myeloid blood cells, most often diagnosed in adults aged 65–74. Many older patients are unfit for intensive induction chemotherapy, leaving hypomethylating agents and supportive care as the historical backbone — a setting with persistent unmet need.
In 2013 the hypomethylating agent (HMA) class was anchored by Celgene's Vidaza (azacitidine) and Astex/Otsuka/Eisai's own Dacogen (decitabine) — both subcutaneous/IV cytidine analogs approved for MDS and unfit AML. Otsuka's $886M acquisition of Astex was built around SGI-110 (guadecitabine), a dinucleotide prodrug of decitabine designed to extend half-life and intracellular exposure, positioned as 'best-in-class' next-generation HMA across AML, MDS, ovarian, and HCC. The strategic case was straightforward: protect HMA franchise economics as Vidaza/Dacogen lost exclusivity, plus add the Pyramid fragment-based discovery platform and HSP90 inhibitor AT13387. The competitive thesis collapsed when guadecitabine missed primary endpoints in ASTRAL-1 (treatment-naive unfit AML, 2018), then ASTRAL-2 and ASTRAL-3 (relapsed/refractory AML and MDS, 2020) — all vs HMA standard of care. Meanwhile, the AML landscape was reshaped by AbbVie/Genentech's Venclexta (venetoclax) + azacitidine combo (2018 accelerated approval), which became the new unfit-AML standard, and by IDH-targeted agents (Tibsovo, Idhifa). Sources: https://www.fiercebiotech.com/biotech/otsuka-s-guadecitabine-flunks-2-more-late-phase-cancer-trials ; https://www.businesswire.com/news/home/20201014005914/en/
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Otsuka Pharmaceutical Co. Ltd. / Astex Pharmaceuticals (this deal) | 2013 | $886M | 79 |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Servier / Shire plc (Oncology Business) | 2018 | $2.4B | 88 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| Shire plc / Baxalta Inc. | 2016 | $32.0B | 77 |
← Browse all deals · How we score deals
More: 2013 deals · Hematology deals